Ryvu Therapeutics (RVU) H1 2024 earnings summary

Executive summary

• Operating revenue rose to PLN 48.5M in H1 2024, up from PLN 33.8M year-over-year, driven by increased sales, R&D project revenues, and subsidies, notably from BioNTech and Exelixis collaborations.

• Net loss widened to PLN 49.8M from PLN 46.1M year-over-year, reflecting higher R&D expenditures despite revenue growth.

• Cash position strengthened to PLN 112.5M as of June 30, 2024, supported by EIB financing tranches; total assets reached PLN 406.6M.

• Pipeline advanced with multiple Phase II studies for RVU120 in AML, HR-MDS, and myelofibrosis, and progress in synthetic lethality and immuno-oncology collaborations.

Financial highlights

• Operating revenue increased by PLN 14.7M year-over-year, mainly from BioNTech and Exelixis agreements.

• Net loss for H1 2024 was PLN 49.8M, up from PLN 46.1M in H1 2023; EBIT loss was PLN 55.3M.

• Cash and cash equivalents rose to PLN 112.5M from PLN 57.9M at year-end 2023.

• Total liabilities increased to PLN 201.2M, mainly due to EIB loans.

• Book value per share decreased to PLN 8.88 from PLN 13.38 at year-end 2023.

Outlook and guidance

• Financial position remains strong with cash of PLN 251.4M as of September 5, 2024, after EIB Tranche C.

• Focus on expanding RVU120 clinical development, advancing preclinical programs, and achieving milestones in R&D collaborations.

• Future revenues depend on successful commercialization of R&D projects.